和铂医药(02142.HK)曾挫15%破底 Immunovant对患者暂停临床用药
和铂医药-B(02142.HK)获悉Immunovant已对患者暂停使用IMVT-1401临床用药,该股扭三连升,今天股价曾急吐15%失守1月13日所创上市低位8.01元,最低见7.88元喘定,现造8.4元,吐近9.8%,一向薄弱成交增至354万股,涉资2,951万元。
和铂公布,已从Immunovant公告中获悉,由於收到实验室血脂指标升高的报告,Immunovant已自行於针对治疗甲状腺眼病患者的2b阶段试验及针对治疗温抗体型自身免疫性溶血性贫血患者的试验中暂停对相关患者使用IMVT-1401的临床用药。Immunovant在大中华区以外的特定地区获授权使用巴托利单抗,并正在美国独立进行试验。
和铂是一家仍处於临床阶段的生物制药公司,主要从事研发免疫与肿瘤疾病领域的差异化抗体疗法。股份於去年12月9日以每股12.38元在港上市,集资净额约15.99亿元。股价挂牌後一直「潜水」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.